Bellevue Group AG Sells 4,000 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)

Bellevue Group AG reduced its holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) by 0.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,460,693 shares of the biopharmaceutical company’s stock after selling 4,000 shares during the quarter. Bellevue Group AG owned 0.07% of Sage Therapeutics worth $32,206,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Headlands Technologies LLC increased its stake in Sage Therapeutics by 245.3% during the 2nd quarter. Headlands Technologies LLC now owns 3,916 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 2,782 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Sage Therapeutics by 66.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 4,672 shares during the period. Creative Planning bought a new stake in shares of Sage Therapeutics during the third quarter worth $88,000. Lazard Asset Management LLC acquired a new stake in shares of Sage Therapeutics during the first quarter worth $127,000. Finally, Quest Partners LLC lifted its position in Sage Therapeutics by 14.5% in the 2nd quarter. Quest Partners LLC now owns 11,763 shares of the biopharmaceutical company’s stock valued at $128,000 after acquiring an additional 1,486 shares in the last quarter. Institutional investors and hedge funds own 99.22% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Royal Bank of Canada upgraded Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 target price for the company in a report on Thursday, November 21st. Scotiabank dropped their target price on Sage Therapeutics from $17.00 to $14.00 and set a “sector outperform” rating on the stock in a research report on Wednesday, October 30th. Needham & Company LLC restated a “hold” rating on shares of Sage Therapeutics in a research note on Wednesday, November 20th. Truist Financial decreased their price target on shares of Sage Therapeutics from $13.00 to $8.00 and set a “hold” rating for the company in a research note on Wednesday, October 30th. Finally, Robert W. Baird cut their price objective on shares of Sage Therapeutics from $13.00 to $9.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 9th. Three research analysts have rated the stock with a sell rating, seventeen have issued a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $12.83.

Sage Therapeutics Trading Down 1.4 %

Shares of NASDAQ SAGE opened at $5.47 on Friday. Sage Therapeutics, Inc. has a 12 month low of $4.62 and a 12 month high of $28.26. The stock has a 50 day moving average of $6.49 and a 200-day moving average of $8.79.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) EPS for the quarter, missing the consensus estimate of ($1.52) by ($0.01). The company had revenue of $11.87 million during the quarter, compared to analyst estimates of $10.80 million. Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. Sage Therapeutics’s revenue for the quarter was up 337.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($2.81) earnings per share. On average, equities analysts anticipate that Sage Therapeutics, Inc. will post -6.53 earnings per share for the current year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.